http://orcid.org/0000-0002-2013-209X
References
- Hart GW, Slawson C, Ramirez-Correa G, et al. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80:825–858.
- Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;259(5):3308–3317.
- Arnold CS, Johnson GVW, Cole RN, et al. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem. 1996;271(46):28741–28744.
- Gong CX, Liu F, Iqbal K. O-GlcNAcylation: a regulator of tau pathology and neurodegeneration. Alzheimers Dement. 2016;12(10):1078–1089.
- Liu F, Iqbal K, Grundke-Iqbal I, et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004;101(29):10804–10809.
- Liu F, Shi J, Tanimukai H, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain. 2009;132(Pt 7):1820–1832.
- Li X, Lu F, Wang JZ, et al. Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci. 2006;23(8):2078–2086.
- Wang AC, Jensen EH, Rexach JE, et al. Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration. Proc Natl Acad Sci U S A. 2016;113(52):15120–15125.
- Liu Y, Liu F, Grundke-Iqbal I, et al. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease. J Neurochem. 2009;111(1):242–249.
- Tramutola A, Sharma N, Barone E, et al. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864(10):3309–3321.
- Bacigalupa ZA, Bhadiadra CH, Reginato MJ. O-GlcNAcylation: key regulator of glycolytic pathways. J Bioenerg Biomembr. 2018;50(3):189–198.
- Zhu Y, Shan X, Yuzwa SA, et al. The emerging link between O-GlcNAc and Alzheimer disease. J Biol Chem. 2014;289(50):34472–34481.
- Frenkel-Pinter M, Shmueli MD, Raz C, et al. Interplay between protein glycosylation pathways in Alzheimer’s disease. Sci Adv. 2017;3(9).
- Yuzwa SA, Shan X, Macauley MS, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012;8(4):393–399.
- Yu Y, Zhang L, Li X, et al. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One. 2012;7(4):e35277.
- Graham DL, Gray AJ, Joyce JA, et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology. 2014;79:307–313.
- Borghgraef P, Menuet C, Theunis C, et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One. 2013;8(12):e84442.
- Hastings NB, Wang XH, Song LX, et al. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener. 2017;12.
- Yuzwa SA, Cheung AH, Okon M, et al. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J Mol Biol. 2014;426(8):1736–1752.
- Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab. 2010;36(6 Pt 1):423–435.
- Bedse G, Di Domenico F, Serviddio G, et al. Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front Neurosci-Switz. 2015;9:1–13.
- Pinho TS, Verde DM, Correia SC, et al. O-GlcNAcylation and neuronal energy status: implications for Alzheimer’s disease. Ageing Res Rev. 2018;46:32–41.
- Jeon BT, Heo RW, Jeong EA, et al. Effects of caloric restriction on O-GlcNAcylation, Ca(2+) signaling, and learning impairment in the hippocampus of ob/ob mice. Neurobiol Aging. 2016;44:127–137.
- Dai CL, Gu JH, Liu F, et al. Neuronal O-GlcNAc transferase regulates appetite, body weight, and peripheral insulin resistance. Neurobiol Aging. 2018;70:40–50.
- Barone E, Tramutola A, Triani F, et al. Biliverdin reductase-A mediates the beneficial effects of intranasal insulin in Alzheimer Disease. Mol Neurobiol. 2018.
- Bennett CE, Johnsen VL, Shearer J, et al. Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice. Life Sci. 2013;92(11):657–663.